We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Risk Factor Identified for Life-Threatening Disease in Premature Infants

By LabMedica International staff writers
Posted on 03 Feb 2014
Many premature infants suffer a life-threatening bowel infection called necrotizing enterocolitis (NEC), and a marker has been identified in those infants who are at risk for the infection.

Since thrombocytopenia and bowel ischemia are consistent findings in advanced NEC, two potential biomarkers, reticulated platelets (RP) and intestinal alkaline phosphatase (iAP), were investigated. More...


Scientists at Loyola University Medical Center (Maywood, IL, USA) prospectively enrolled 177 infants born at less than 32 weeks' gestation and who were less than 1,500 grams in weight, from 2009 to 2012. Blood samples were collected from these infants within 72 hours of birth and weekly for four weeks to measure reticulated platelets (RP) and intestinal alkaline phosphatase (iAP). The percentage of reticulated platelets was determined by flow cytometry and serum iAP levels were determined by gel electrophoresis.

Of the 177 infants, 15 (8.5%) developed NEC and of these, 93% had low RP levels and 60% had high iAP. Those infants with low RP levels were significantly more likely to develop NEC while those with high iAP showed a similar trend. The study found that infants who would go on to develop NEC had significantly higher iAP levels at week four. While classically NEC occurs at week three of life, feeds of infants in the neonatal intensive care unit are advanced slowly and typically not started until near the end of the first week. The later initiation of feeds in the preterm infants in the study might be a reflection of them being extremely low birthweight infants (birthweight less than 1,000 g) and unstable at birth, delaying the onset of enteral feeds.

The authors concluded that as NEC affects up to 10% of very low birthweight infants, an already vulnerable population, it is important to discover reliable tests to detect those infants in this subpopulation who are most at risk of developing NEC in order to work towards prevention. Currently, no one test exists that can predict NEC; however, the team’s study suggests that the findings of low reticulated platelets and a high iAP may be useful in identifying those preterm infants at risk of NEC. Jonathan Muraskas, MD, the senior author, said, “Decreased reticulated platelets serve as a sensitive indicator for NEC onset. Further research also may find that infants with elevated iAP levels may be at risk.” The study was published online in the November 2013 issue of the Journal of Pediatric Surgery.

Related Links:

Loyola University Medical Center



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.